About this Journal Submit a Manuscript Table of Contents
Pulmonary Medicine
Volume 2012 (2012), Article ID 545172, 9 pages
Research Article

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects

Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USA

Received 6 May 2011; Accepted 26 August 2011

Academic Editor: Athol Wells

Copyright © 2012 Galina S. Bogatkevich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [2 citations]

The following is the list of published articles that have cited the current article.

  • Brad Rybinski, and Janusz Franco-Barraza, “The wound healing, chronic fibrosis, and cancer progression triad,” Physiological Genomics, vol. 46, no. 7, pp. 223–244, 2014. View at Publisher · View at Google Scholar
  • Tanjina Akter, Richard M. Silver, and Galina S. Bogatkevich, “Recent Advances in Understanding the Pathogenesis of Scleroderma-Interstitial Lung Disease,” Current Rheumatology Reports, vol. 16, no. 4, 2014. View at Publisher · View at Google Scholar